Table 1. Baseline characteristics of the study population.
| No. of patients | |
|---|---|
| Parameter | (n = 45) |
| Median age, yr (range) | 53 (36–69) |
| Sex | |
| Female/Male | 19/26 |
| Underlying disease | |
| Acute myelogenous leukemia | 23 |
| Malignant lymphoma | 10 |
| Acute lymphoblastic leukemia | 5 |
| Myelodysplastic syndrome | 5 |
| Primary myelofibrosis | 1 |
| Aplastic anemia | 1 |
| Risk status at transplantation | |
| Standard/High | 22/23 |
| Conditioning regimen | |
| Myeloablative/Reduced intensity | 20/25 |
| Total body irradiation | |
| None | 10 |
| Low-dose/High-dose | 21/14 |
| Graft source | |
| Bone marrow | 21 |
| Peripheral blood | 20 |
| Cord blood | 4 |
| HLA parity | |
| Matched/Mismatched | 24/21 |
| Antibiotic use during conditioning | |
| Prophylactic/Treatment use | 19/26 |
| GvHD prophylaxis | |
| CIs+sMTX | 32 |
| CIs+MMF±PTCy | 9 |
| Others | 4 |
| Prior transplantation | |
| Yes/No | 6/39 |
| Median number of teeth (range) | 27 (5–32) |
| Bacteremia until day+100 | |
| Yes/No | 12/33 |
| Oral mucositis | |
| Yes/No | 28/17 |
| Grade 2 to 4 | 25 |
| Grade 3 to 4 | 15 |
| Acute GvHD | |
| Yes/No | 25/20 |
| Grade II to IV | 15 |
| Grade III to IV | 4 |
Abbreviation: GvHD, graft-versus host disease, CIs, calcineurin inhibitors; MTX, methotrexate; MMF, mycophenolate mofetil; PTCy, post-transplant cyclophosphamide